Dr Bożena Walewska-Zielecka becomes new Medical Director and joins the Medicover Board

Dr Bożena Walewska-Zielecka becomes new Medical Director and joins the Medicover Board

Published

In June of this year, Dr Bożena Walewska-Zielecka was appointed to the Management Board of Medicover Sp. z o.o. and took over the post of Medical Director at Medicover. In her new role she will be responsible for medical quality, occupational medicine, prevention standards and the quality and risk management system, among others.

Dr Bożena Walewska-Zielecka became a new member of the Management Board of Medicover Sp. z o.o. At the same time, she assumed the position of Medical Director. Previously, she served as Deputy Clinical Director. She has been with Medicover since 1995.

The many years of experience gained at our company guarantees an excellent understanding of its functioning, priorities and key needs. Dr Bożena Walewska-Zielecka’s knowledge of Medicover combined with her medical and managerial experience will support the effective development of her department, 

comments Mirosław Suszek, Vice President of the Management Board, Director of Operations and Medical Division at Medicover Polska.

Bożena Walewska-Zielecka holds a PhD degree in medical sciences, is a pathologist, travel medicine physician and a specialist in liver disease. She also gained broad experience as a lecturer and researcher at Warsaw Medical University.
At the same time, Dr Piotr Soszyński took over the newly created position of Director of Medical Systems. He will be responsible for the maintenance and development of medical systems, supervising authorisations and access to the systems, as well as information security, including protecting medical information, along with the necessary adaptations to the new EU legal requirements, and cooperation with other innovation development teams.

Copy as a Plain Text

Share

Related Stories
How much can we benefit from effective healthcare?

ago

PLN 726 per employee for each employer, more than PLN 11 billion in savings to the Treasury, are the savings which can be achieved thanks to investment in effective, quality healthcare, according to the authors of the report: “Work. Health. Economics. A 2012-2016 Perspective”, prepared by Medicover Polska. However, experts point out that the key to success is to bring the healthcare model in line with the healthcare needs of the economically active. Therefore, the key objective of this year’s analysis was to answer the question “How healthy are employees in Poland?”
4D ultrasound – an advanced method for foetal imaging

ago

Obligatory tests for pregnant women in Poland include 2D ultrasound scan, which is a non-invasive imaging ultrasound check. The scan gives the opportunity to detect any potential abnormalities in the foetus at different stages of pregnancy. Even more diagnostic possibilities are available with the new 4D method as it allows for dimensional imaging of the baby in real time.
10 platinum minutes for life

ago

The “Safe Company” Anniversary Medical Rescue Championships
Skin exam after holidays

ago

Melanoma is one of the most dangerous skin neoplasm that, in many cases, may give spreads at an early stage. At the moment, it is the most frequent cause of death due to skin cancer. Melanoma is visible on the skin very quickly at early stages of its development, therefore doctors recommend self-examination of pigmented moles once a month. In particular, we should pay attention to moles that are irregular in shape, of uneven edges, multi-colour, changing in a short time and exceed 5 mm. When any suspicious changes are noticed, it is advisable to see a doctor who will carry out relevant diagnostic tests – dermoscopy and video-dermoscopy.

Medicover first in Europe to launch pilot project aimed at identifying patients at risk of colorectal cancer

Medicover Polska is testing the ColonFlag modern solution that will allow to effectively identify patients at risk for colorectal cancer. The tool determines the risk of intestinal lesions by further analysing the results of a commonly performed blood test. The pilot project is being developed in collaboration with Medial EarlySign, an Israeli company that creates machine-learning systems in the area of data-driven medicine.